- Home
- CFR vs LNTH Comparison
CFR vs LNTH Comparison
Compare CFR & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFR
- LNTH
- Stock Information
- Founded
- CFR 1868
- LNTH 1956
- Country
- CFR United States
- LNTH United States
- Employees
- CFR N/A
- LNTH N/A
- Industry
- CFR Major Banks
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CFR Finance
- LNTH Health Care
- Exchange
- CFR Nasdaq
- LNTH Nasdaq
- Market Cap
- CFR 7.9B
- LNTH 7.5B
- IPO Year
- CFR N/A
- LNTH 2015
- Fundamental
- Price
- CFR $127.98
- LNTH $76.41
- Analyst Decision
- CFR Hold
- LNTH Strong Buy
- Analyst Count
- CFR 15
- LNTH 5
- Target Price
- CFR $133.13
- LNTH $133.80
- AVG Volume (30 Days)
- CFR 367.4K
- LNTH 1.4M
- Earning Date
- CFR 05-01-2025
- LNTH 05-07-2025
- Dividend Yield
- CFR 3.05%
- LNTH N/A
- EPS Growth
- CFR 7.71
- LNTH N/A
- EPS
- CFR 9.11
- LNTH 3.53
- Revenue
- CFR $2,038,108,000.00
- LNTH $1,536,699,000.00
- Revenue This Year
- CFR $11.62
- LNTH $4.96
- Revenue Next Year
- CFR $3.90
- LNTH $10.25
- P/E Ratio
- CFR $14.41
- LNTH $23.00
- Revenue Growth
- CFR 5.45
- LNTH 12.53
- 52 Week Low
- CFR $94.09
- LNTH $74.34
- 52 Week High
- CFR $147.64
- LNTH $126.89
- Technical
- Relative Strength Index (RSI)
- CFR 61.36
- LNTH 28.54
- Support Level
- CFR $129.20
- LNTH $77.01
- Resistance Level
- CFR $131.80
- LNTH $81.50
- Average True Range (ATR)
- CFR 2.20
- LNTH 3.43
- MACD
- CFR 0.69
- LNTH -1.52
- Stochastic Oscillator
- CFR 75.00
- LNTH 0.88
About CFR Cullen/Frost Bankers Inc.
Cullen/Frost is a regional US bank with around $50 billion in assets (as of 2024 year-end), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.